Comparison between long- and short-acting erythropoiesis-stimulating agents in the period required for haemoglobin stabilisation in treatment of anaemia in patients with chronic kidney disease

Takahiro Hayashi, Tadashi Nagamatsu, Ayako Matsushita, Tomohiro Mizuno, Seira Nishibe, Ayaka Noguchi, Rina Kato, Takahiro Toda, Junko Tanaka, Hiroshi Takahashi, Hiroki Hayashi, Yukio Yuzawa, Shigeki Yamada

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Comparative studies of the potency of long- and short-acting erythropoiesis-stimulating agents (L-ESAs and S-ESAs) on erythropoietic activity in patients with chronic kidney disease without dialysis have not been performed, although L-ESAs are used in many countries. We performed a retrospective analysis of non-dialysis (ND) patients who had received L-ESA or S-ESA. More days were needed for the S-ESA-treated group (368 d) to reach the haemoglobin (Hb) reference range than for the L-ESA-treated group (126 d). Therefore, we investigated risk factors that influence the period until the Hb level reaches the reference range. Patients were classified into two groups by the period until the Hb level was stabilised within the reference range: the short- and long-term group. Two risk factors for delayed Hb stabilisation were identified: age ≥60 years; and administration of an S-ESA for initial treatment. These findings suggest that the Hb level should be carefully monitored during ESA therapy in elderly ND patients, and that the ESA dose should be increased or L-ESA therapy should be utilised to treat renal anaemia.

Original languageEnglish
Pages (from-to)740-745
Number of pages6
JournalBiological and Pharmaceutical Bulletin
Volume38
Issue number5
DOIs
Publication statusPublished - 01-05-2015

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Pharmaceutical Science

Fingerprint Dive into the research topics of 'Comparison between long- and short-acting erythropoiesis-stimulating agents in the period required for haemoglobin stabilisation in treatment of anaemia in patients with chronic kidney disease'. Together they form a unique fingerprint.

  • Cite this